Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.61 |
| ▸ | CA1 | P00915 | 6/20 | 0.61 |
| ▸ | CA12 | O43570 | 3/20 | 0.61 |
| ▸ | CA4 | P22748 | 3/20 | 0.61 |
| ▸ | CA6 | P23280 | 3/20 | 0.61 |
| ▸ | CA5A | P35218 | 3/20 | 0.61 |
| ▸ | CA7 | P43166 | 3/20 | 0.61 |
| ▸ | CA9 | Q16790 | 3/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.61 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP7 | P09237 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP14 | P50281 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL156259 | 0.80 | CA2 (0.67) | CA2CA1CA12CA4CA6 | |
| SCHEMBL11582128 | 0.80 | ALDH1A1 (0.52) | CA2CA1CA12CA4CA6 | |
| SCHEMBL2263958 | 0.80 | ALDH1A1 (0.52) | CA2CA1CA12CA4CA6 | |
| SCHEMBL14834008 | 0.80 | ALDH1A1 (0.52) | CA2CA1CA12CA4CA6 | |
| SCHEMBL651902 | 0.79 | ALDH1A1 (0.71) | CA2CA1CA12CA4CA6 | |
| SCHEMBL505826 | 0.78 | CA2 (0.64) | CA2CA1CA12CA4CA6 | |
| SCHEMBL396619 | 0.78 | ALDH1A1 (0.50) | CA2CA1CA12CA4CA6 | |
| SCHEMBL27749399 | 0.77 | ALDH1A1 (0.44) | CA2CA1CA12CA4CA6 | |
| SCHEMBL1597654 | 0.76 | ALDH1A1 (0.48) | CA2CA1CA12CA4CA6 | |
| SCHEMBL1009797 | 0.76 | CA2 (1.00) | CA2CA1CA12CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695232-A1 | COMPOUNDS AND PROCESSES RELATED TO FLUMETYLSULFORIM | ADAMA MAKHTESHIM LTD. (IL) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024214047-A9 | COMPOUNDS AND PROCESSES RELATED TO FLUMETHYLSULFORIM | ADAMA MAKHTESHIM LTD. (IL) | 2025-05-30 | — | — | WO | disclosed |
| WO-2024214047-A1 | COMPOUNDS AND PROCESSES RELATED TO FLUMETHYLSULFORIM | ADAMA MAKHTESHIM LTD. (IL) | 2024-10-17 | — | — | WO | disclosed |
| US-11826315-B2 | STAT3 inhibitors | Tvardi Therapeutics (US) | 2023-11-28 | — | — | US | disclosed |
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-04-12 | — | — | US | disclosed |
| US-20160271130-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORP. (US) | 2016-09-22 | — | — | US | disclosed |
| EP-2285384-A2 | BORON-CONTAINING SMALL MOLECULES | Anacor Pharmaceuticals, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20110028469-A1 | Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor | ANDERSON ERIC C | 2011-02-03 | — | — | US | disclosed |
| US-20100256092-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| WO-2009140309-A2 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| EP-1165510-B1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| CN-1150165-C | 1-arylsulfonyl-2-aryl-pyrrolidine derivatives for the treatment of central nervous system disorders | - | 2004-05-19 | — | — | CN | disclosed |
| CN-1345311-A | 1-arenesulfonyl-2-aryl-pyrolidine and piperidine derivatives for treatment of CNS disorders | HOFFMANN LA ROCHE (CH) | 2002-04-17 | — | — | CN | disclosed |
| EP-1165510-A1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-02 | — | — | EP | disclosed |
| US-6284785-B1 | HAVING ACTIVITY AS LIGANDS OF METABOTROPIC GLUTAMATE RECEPTORS | HOFFMANN- LA ROCHE INC. | 2001-09-04 | — | — | US | disclosed |
| WO-2000058285-A1 | 1-ARENESULFONYL-2-ARYL-PYRROLIDINE AND PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-10-05 | — | — | WO | disclosed |
| US-5578633-A | VASOPRESSIN AND OXYTOCIN ANTAGONISTS | SANOFI (FR) | 1996-11-26 | — | — | US | disclosed |
| US-5481005-A | N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present | SANOFI (FR) | 1996-01-02 | — | — | US | disclosed |
| US-5397801-A | Affinity for vasopressin and ocytocin receptors; disorders of nervous, cardiovascular and gastrointestinal systems | SANOFI (FR) | 1995-03-14 | — | — | US | disclosed |
| US-5338755-A | Have affinity for vasopressin and ocytocin receptors; intermediates for drugs that act on central nervous system | ELF SANOFI (FR) | 1994-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271130-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | HAVCR2, MAVS, HCCS | CA2 4696/4885CA1 4592/4885CA12 4490/4885 |
| US-20110028469-A1 | Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor | CCR9, CCR1, CCR10 | CA2 1023/4885CA1 1122/4885CA12 1417/4885 |
| US-20180099952-A1 | HEPATITIS B VIRAL ASSEMBLY EFFECTORS | HAVCR2, MAVS, HCCS | CA2 4696/4885CA1 4592/4885CA12 4490/4885 |
| US-11826315-B2 | STAT3 inhibitors | STAT3, JAK2, STAT1 | CA2 3008/4885CA1 4222/4885CA12 3566/4885 |
| US-20100256092-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BCL6, BTD | CA2 1155/4885CA1 4452/4885CA12 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.